- This event has passed.
Taltz® (ixekizumab) injection 80mg/mL: A COAST-to-COAST Treatment
November 8, 2021 from 12:30 pm - 1:30 pm EST
Taltz® (ixekizumab) injection 80mg/mL: A COAST-to-COAST Treatment for the Spectrum of axSpA (AS and nr-axSpA)
Join presenters Hillary Norton, MD, and Pendleton Wickersham, MD, as they review an IL-17A antagonist with efficacy across the spectrum of axial spondyloarthritis (axSpA) in both ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). The presenters will begin with an overview of the disease state, followed by a robust discussion on Taltz efficacy and safety information.
Visit lilly-virtual.com/taltz to learn about additional Taltz Industry Sessions and Presenters, and discover the Taltz difference season to season!
This program is developed and offered by Lilly USA, LLC. This is not an official program of the American College of Rheumatology.
Indications and Important Safety Information
Taltz is indicated for adults with active psoriatic arthritis (PsA), for adults with active ankylosing spondylitis (AS), and for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. Taltz is also indicated for patients aged 6 years or older with moderate- to-severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONS
Taltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the. Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel Disease
Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis.
Please see full Prescribing Information and Medication Guide for Taltz. See Instructions for Use included with the device.
IX HCP ISI 07MAY2020
Taltz® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. PP-IX-US-5030 09/2021 ©Lilly USA, LLC 2021. All rights reserved.
This is not an official function/event of the American College of Rheumatology.